SAR125844

DRUG3 trials

Sponsors

Sanofi

Conditions

Malignant Solid TumorsNeoplasm Malignant

Phase 1

Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

CompletedNCT01391533

SanofiMalignant Solid Tumors

Start: 2011-07-31End: 2016-04-30Updated: 2016-04-13

Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients

CompletedNCT01657214

SanofiNeoplasm Malignant

Start: 2012-09-30End: 2016-01-31Updated: 2016-02-17

Phase 2

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

CompletedNCT02435121

SanofiNeoplasm Malignant

Start: 2015-11-30End: 2016-01-31Updated: 2016-03-23

Related Papers

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

European Journal of Cancer2017-11-1438 citations

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i>-amplified gastric cancer

Oncotarget2017-06-1625 citations

MET aberrations across multiple tumor types: Results of a molecular screening program (MOSCATO 01).

Journal of Clinical Oncology2017-05-20

Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors

Molecular Cancer Therapeutics2015-12-012 citations

A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.

Journal of Clinical Oncology2014-05-205 citations